Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.63 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.63 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.63 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11551428 | 0.87 | POLB (0.75) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL11325469 | 0.87 | LMNA (0.83) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL6789579 | 0.85 | POLB (0.68) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL1745798 | 0.84 | KMT2A (0.71) | POLBALDH1A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL30388225 | 0.84 | KMT2A (0.71) | POLBALDH1A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL1335449 | 0.83 | POLB (1.00) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| Acetic Acid SCHEMBL29589279 | 0.83 | POLB (0.69) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| Acetic Acid SCHEMBL28756645 | 0.83 | POLB (0.69) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL6205171 | 0.82 | KMT2A (0.54) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL11323044 | 0.82 | LMNA (0.71) | POLBLMNAALDH1A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611109-A4 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-06-24 | — | — | EP | claimed |
| JP-2006522109-A | — | — | 2006-09-28 | — | — | JP | claimed |
| EP-1611109-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-01-04 | — | — | EP | claimed |
| WO-2004087680-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-14 | — | — | WO | claimed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-0743946-A1 | 5HT2B RECEPTOR ANTAGONISTS CONDENSED INDOLES | SMITHKLINE BEECHAM PLC (GB) | 1996-11-27 | — | — | EP | disclosed |
| US-5508288-A | Indole derivatives as 5HT1C antagonists | SMITHKLINE BEECHAM, P.L.C. (GB) | 1996-04-16 | — | — | US | disclosed |
| WO-1995021844-A1 | 5HT2B RECEPTOR ANTAGONISTS CONDENSED INDOLES | SMITHKLINE BEECHAM PLC (GB) | 1995-08-17 | — | — | WO | disclosed |
| EP-0656003-A1 | CONDENSED INDOLE DERIVATIVES AS 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-07 | — | — | EP | disclosed |
| EP-0630373-A1 | INDOLE DERIVATIVES AS 5HT1C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-12-28 | — | — | EP | disclosed |
| US-5328922-A | Anxiolytic and antidepressant activity | BEECHAM GROUP P.L.C. (GB) | 1994-07-12 | — | — | US | disclosed |
| WO-1994004533-A1 | CONDENSED INDOLE DERIVATIVES AS 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-03-03 | — | — | WO | disclosed |
| WO-1993018026-A1 | INDOLE UREAS AS 5-HT1C RECEPTOR ANTOGONISTS | BEECHAM GROUP PLC (GB) | 1993-09-16 | — | — | WO | disclosed |
| WO-1993018028-A1 | INDOLE DERIVATIVES AS 5HT1C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-09-16 | — | — | WO | disclosed |
| WO-1993016694-A1 | USE OF INDYLPYRIDYLUREAS TO HEAL THE EFFECTS OF BRAIN OR SPIRAL TRAUMA | SMITHKLINE BEECHAM PLC (GB) | 1993-09-02 | — | — | WO | disclosed |
| EP-0550507-A1 | INDOLE UREAS AS 5 HT RECEPTOR ANTAGONIST | Beecham Group p.l.c. (GB) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992005170-A1 | INDOLE UREAS AS 5 HT RECEPTOR ANTAGONIST | BEECHAM GROUP PLC (GB) | 1992-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | POLB 4518/4885LMNA 2932/4885ALDH1A1 2069/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | POLB 3369/4885LMNA 3391/4885ALDH1A1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.